Proveris SCIENTIFIC
WHITE PAPERS
Learn more about how Proveris products and services are eliminating testing variables and helping to accelerate OINDP development.
Oral and Nasal
Windows 10 Support Has Ended. Is Your Lab Prepared?
With Windows 10 support ending in October 2025, regulated laboratories face increased cybersecurity and compliance challenges. Download our white paper, Staying Audit-Ready After Windows 10 End-of-Support, to learn how to assess your systems, manage risk, and plan a smooth transition to Windows 11. The white paper explores:
- The impact of Windows 10 end-of-support
- Extended Security Update (ESU) options and limitations
- Risks of remaining on unsupported systems
- Best practices for compliant migration planning
- How to evaluate readiness with a 10-point checklist
Spray Pattern and Plume Geometry: Regulatory Convergence and Technological Innovation in Inhaled and Nasal Drug Products
This article explores the evolving regulatory role of Spray Pattern and Plume Geometry testing in inhalation and nasal drug product development, highlighting their formal recognition in the February 2026 update to the European Medicines Agency (EMA) guideline on pharmaceutical quality. It examines how advances in high-speed imaging and automated analysis have transformed these tests into dynamic, data-rich tools that support product development, comparability assessments, and lifecycle management.
Proveris by Design™: A roadmap for in vitro characterization of orally inhaled and nasal drug products
Liao L., Proveris Scientific White Paper. Proveris Scientific Corporation, 2020 November.
Part 1: Stepwise guide to development of nasal sprays and pMDIs – a Proveris by Design™ approach
Part 2: Using a novel human realistic approach for in vitro characterization to better predict in vivo performance of inhaled aerosols
Reducing variability in test results for OINDPS with automated actuation
Chauhan H., Liao L., Proveris Scientific White Paper. Proveris Scientific Corporation, 2018 November.
Proveris Scientific discusses the importance of automated actuation for testing inhalation and spray devices to avoid variability introduced by manual methods, and how Proveris’s portfolio of instruments and services can ensure the accuracy and reproducibility of results.
What is Quality by Design and why should you care?
Newcomb A., Liu-Cordero S., Proveris Scientific White Paper. Proveris Scientific Corporation, 2017 March.
Quality by Design (QbD) is a scientific approach that formalizes product design, automates manual testing, and streamlines troubleshooting. A QbD approach is an indispensable tool for successfully developing inhaled and nasal drug products as well as critical to creating effective manufacturing processes for released products.
Oral
The Next Frontier for Inhaled Therapies: Low-GWP Propellants and the Future of pMDI Development
Mather, J., Article Reprint from International Pharmaceutical Industry Journal, Summer 2025 Issue. Proveris Scientific Corporation, 2025
Exploring the Performance of Low-GWP Propellants
Advancing the Science: Exploring New Alternative In Vitro Tests to Help Demonstrate Bioequivalence in Inhalation Products
Proveris Scientific Technical Article. Proveris Scientific Corporation 2022 November.
Reprint from ONdrugDelivery Magazine, 2022 November.
Spray Pattern: A rapid and sensitive early development tool for respiratory drug products
Liao L., Chauhan H., Newcomb A., L’Ecuyer T., Liu-Cordero S., Leveille C., Article Reprint from Inhalation Magazine. Proveris Scientific Corporation, 2017 October.
Utilizing spray performance measurements to accelerate OINDP development.
Complete solution for pMDI products: From development to quality control testing
Chauhan H., Proveris Scientific White Paper. Proveris Scientific Corporation, 2018 November.
Proveris Scientific outlines the major challenges encountered in testing pressurized metered dose inhalers, and how Proveris’s portfolio of instruments can be an invaluable addition to the testing workflow.
Nasal
The Role of Ergonomic Studies and Automated Solutions in Nasal Drug Product Development
Thurston, G., Article Reprint from International Pharmaceutical Industry Journal, Spring 2025 Issue. Proveris Scientific Corporation, 2025
Emerging Trends in Nasal Spray Development: Tools for Future Success
Vereo® SWC: A benchtop workstation for nasal spray testing. From complexity to control in nasal spray testing.
Article Reprint from PMPS Inhalation Technology Supplement, Spring 2026 Issue. Proveris Scientific Corporation, 2026
Spray pattern as a screening tool during early development of nasal sprays
Heli Chauhan, MS, and Linda (Lingzhi) Liao, MS, Proveris Scientific Technical Article. Proveris Scientific Corporation, 2019 June. Reprint from Inhalation Magazine, 2019 June.
Using spray pattern to select an optimum device/formulation combination.
Addressing the challenges in nasal device testing: Evaluation of pump performance
Chauhan H., Proveris Scientific White Paper. Proveris Scientific Corporation, 2018 November.
Proveris Scientific addresses the challenges faced by the OINDP industry, with a particular emphasis on nasal spray devices. Solutions are offered in the form of the fully automated Indizo® system and Vereo® actuators. These instruments expedite
the analysis by effectively streamlining the workflow and eliminating manual processes. They can be used to conduct a variety of the required regulatory tests in a reproducible manner while simulating human use of the product.
Point of view: Inconsistency, confusion and lack of consensus due to the USP Chapter update on nasal delivered dose uniformity (DDU) testing.
Grant Thurston, MSc, Proveris Scientific Opinion Article. Proveris Scientific Corporation. Reprint from Inhalation Magazine, 2025 June.
In this opinion article, the author discusses concerns and presents a supporting case study.
Navigating the USP 601a Update for Nasal Delivered Dose Uniformity
In 2022, the U.S. Pharmacopeia (USP) Chapter <601> introduced a significant change to the testing procedures for nasal spray and aerosol products, causing confusion in the industry. Specifically, the new guidelines recommend using the DUSA (Dosage Unit Sampling Apparatus) tubes for nasal Delivered Dose Uniformity (DDU) testing. However, these updates contradict existing product-specific monographs, creating inconsistencies that could compromise product quality, increase testing costs, and lead to operational inefficiencies.
Evaluating a New Option for Delivered Dose Uniformity: Proveris DUSA Tubes
COVID-19 Partnering Supplement
Proveris Laboratories: Your trusted partner in OINDP Development
In vitro technologies and tools accelerate products to market
Flaherty I., BS, Article Reprint from International Pharmaceutical Industry, COVID-19 Supplement, 2021 January. Proveris Scientific Corporation, 2021 January.
Respiratory Drug Development
Farina, D., MS Eng, Article Reprint from International Pharmaceutical Industry Journal, Spring 2021 Issue. Proveris Scientific Corporation, 2021 April
Perspective from Spray and Aerosol Characterization Expert